SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jaybe11/28/2015 3:09:44 PM
1 Recommendation

Recommended By
ghmm

  Read Replies (1) of 4474
 
Interview with Ariad GM of France, Olivier Polley...

Highlight:
[In the next few years]..."we would ideally also have two to four new drugs in clinical studies, developed from our in-house R&D.

Lowlight:
"From our perspective, it is difficult to understand how France can price drugs at a level 30 to 40 percent lower than other similar European markets, like Germany or Italy."

pharmaboardroom.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News